bevacizumab,trifluridine tipiracil
taiho pharma,roche,otsuka
[]
the sunlight trial of lonsurf +/- bev in refractory mcrc, presented by , met its primary endpoint with improved os by 3.3 months and improvement in qol endoints as well. a new soc #gi23 
MD/PhD Heme/Onc fellow @WUSTL
GI cancers || single-cell genomics
Proud dad, fish keeper, language learner
https://t.co/m7AbNIgWB4 || https://t.co/4Nu6wdD8o7